Clinicoradiological and demographic
pattern in diffuse parenchymal lung diseases:
An observational study
Yadav H1,
Srivastava R.2
1Dr Harendra Yadav, Pulmonary
Medicine, KGMU, Lucknow, Uttar Pradesh 2Dr
Rahul Srivastava, Pulmonary Medicine, Assistant Professor, Hind institute of
Medical Sciences, Safedabad, Barabanki, Uttar Pradesh, India
Corresponding Author: Dr Rahul Srivastava, Pulmonary Medicine, Assistant
Professor, Hind Institute of Medical Sciences, Safedabad, Barabanki, Uttar
Pradesh. Email: rsrahulvijay6@gmail.com
Abstract
Introduction: Diffuse parenchymal disease is a
group of lung disease affecting alveolar epithelium, pulmonary capillary endothelium,
basement membrane, perivascular and perilymphatic tissue. It includes many
diseases like IPF, Sarcoidosis, BOOP, COP, LAM etc. it is still under diagnosed
entirety. Many patients die due to lack of awareness and investigating
modalities. Aims and objective: This
study is to see Demographic pattern of DPLD, its clinical pattern and
radiological findings in different type of ILDs. Study Type: It is a Prospective Observational Study done over a
period of 1 year. Material & Method:
Patients studied over20 years of age and having respiratory symptoms. We
excluded patients of other diseases like COPD, Tuberculosis etc. Total 75
patients were diagnosed as a case of DPLD by clinical findings, and
investigations like X ray chest, HRCT thorax, Bronchoscopy. Results: Most common ILD (Interstitial
lung Disease) is IPF 40.0% followed by Sarcoidosis etc. Most common clinical
symptom was breathlessness (100.00%) in IPF, Fever & Chest Pain are common
in Granulomatous type. Conclusion: DPLD
(Diffuse Paranchymal lung Disease) is a chronic lung disease characterized by
progressive decline in lung function. IPF is most common in DPLD and leads to
fast deterioration of lung function. HRCT (High Resolution computed tomography)
is very important to assess type of disease. Spirometry, Broncoscopy are
important for diagnosis of ILD and lung function.
Key words: DPLD, ILD, IPF, Sarcoidosis, Lung,
Fibrosis
Author Corrected: 28th July 2018 Accepted for Publication: 2nd August 2018
Introduction
DPLD is a
group of lung disorders having over 200 types of disease. DPLD is characterized
by acute or chronic inflammation leading to mild to severe fibrosis [1]. DPLD
includes number of disorders like IPF, Sarcoidosis, Hypersensitivity
Pneumonitis, LAM, NSIP etc. Diagnosing ILD is not easy, it needs through knowledge
and clinical experience. Most definitive diagnostic tool is Histopathology
which is not always possible due to lot of factors like patients clinical
condition and availability of other diagnostic tools like CT and bronchoscopy.
Now DPLD is diagnosed by clinicoradiological ground because of high quality of
High resolution CT, and bronchoscopy, still histopathology is used in many
cases where ever feasible. IPF Is most common and having high mortality. The
Incidence of DPLD range from12 -26/lacs/year. Prevalence of Preclinical and
undiagnosed ILD is estimated to be 10 times of that is clinically recognized
disease. The US prospective registry showed that 23% of cases with ILD were
diagnosed with IPF [2]. .DPLD is classified in four categories. 1. ILD of Known cause: it includes
ILD due to Drugs, Collagen vascular diseases etc. 2. Idiopathic Interstitial Pneumonia. 2a. IPF (idiopathic Pulmonary fibrosis). 2b: Idiopathic pneumonias other than IPF like NSIP (Nonspecific
Interstitial Pneumonia), COP(Cryptogenic Organizing Pneumonia),
RBILD(Respiratory broncheolitis Interstitial lung disease),DIP(desquamative
Interstitial Pneumonia),LIP(Lymphoid Interstitial Pneumonia),AIP(Acute
Interstitial pneumonia). 3.
Granulomatous DPLD like Sarcoidosis. 4.Other
forms like Lymphangioleomyomatosis (LAM), Langerhans Histiocytosis (LH) etc
[1&3]. The IPF was initially considered to be a rare disease in India [4].
Besides IPF other forms like NSIP is common, Most of the times NSIP is
associated with connective tissue disorders, many forms like hypersensitivity
pneumonitis are due to hypersensitivity due to pigeon feather and other forms
of dusts. DPLD is having variety of diseases which are having many symptoms
like cough breathlessness, fever, many connective tissue disorders related
DPLDs have other symptoms also like joint pain, Raynod’s phenomenon etc. Pedal
edema, Cynosis and clubbing is also common in many forms of ILDs. In late and
advanced stage of ILD due to development of PAH (Pulmonary artery Hypertension)
patient develops raised JVP, and pedal edema. Patient of DPLD if not diagnosed
early may land up in Type 1 or type 2 respiratory failure and in further
advancement of disease may require Noninvasive or invasive mechanical
ventilation. In this study we collect data of frequency and type of DPLD at
tertiary care center and clinical profile of patients in various forms.
Aims and Objectives
To study
clinicoradiological pattern and demographic distribution of DPLD in tertiary
care center
Material and Method
Type of Study: Prospective observational study
Place of Study: Patient attending the outdoor/indoor
wards of Pulmonary medicine and Rheumatology Department of King George Medical
University), Lucknow. Study period From September 2010 to August 2011.
Sampling Method: Patients attending OPD & IPD
Department having clinical symptoms suggestive of interstitial lung disease
were taken and through clinical history was taken followed by X-ray, HRCT &
Bronchoscopy was done. Spirometry was done to evaluate lung function.
Patients
were divided four groups for study Group 1 granulomatous type were included in
having sarcoidosis. Group 2 contains IIP (Idiopathic Interstitial Pneumonia)
includes COP (Cryptogenic Organizing Pneumonia), IPF (Idiopathic Pulmonary
Fibrosis), NSIP (Non-Specific interstitial Pneumonia). Group 3: (Known cause)
Drug induced BOOP (Bronchiolitis Obliterans Organizing Pneumonia), Drug induced
NSIP (Non-Specific interstitial Pneumonia), Silicosis, SLE (Systemic Lupus
Erythematosus). Group 4: (Others) EP (Eosinophilic Pneumonia), HP
(Hypersensitivity Pneumonitis), LAM (Lymphangioleomyomatosis), LCH (Langerhans
cell histiocytosis). [1&3].
Inclusion Criteria- Age > 20YearsPatients who had
been diagnosed to have different types of DPLD using the American Thoracic Society/European
Respiratory Society International Multidisciplinary Consensus Classification of
the Diffuse Parenchymal Lung Disease.
Exclusion Criteria- Patients having other associated
significant bronchopulmonary disease like:
1. Pulmonary tuberculosis.
2. COPD
3. Bronchiectasis
4. Asthma
5. Pyogenic Pneumonia
6. Bronchogenic carcinoma
7. known HIV positive
8. Patient taking
Immunomodulating drugs
Method: After review of clinical history,
physical examination along with all investigations, patients were finally
included or excluded from the study.
Following
methods were employed for study
1. Detailed
Clinical History: All the patients were administered a questionnaire regarding
the presence of respiratory complaints. These include cough, expectoration,
breathlessness, wheezing, chest pain, hemoptysis, stridor and hoarseness of
voice. Only the patients with one or any of these symptoms were included in
detail.
❖
Duration of onset of respiratory symptoms.
❖
Duration between establishment of connective
tissue disorder and onset of respiratory symptoms.
❖
Duration between onset of respiratory symptoms
and first visit to physician.
❖
To which Department (Rheumatology/Pulmonary
Medicine) the patient first presented.
❖
What was the progression of Symptoms.
In how many patients cough was the initial symptom, which was
followed by breathlessness and vice-versa. The number of patients in whom fever
was the initial symptom followed by cough and breathlessness / breathlessness
and cough was studied.
2. Clinical
Examination: General
Examination, Respiratory Examination, Rheumatological Examination, Systemic
Examination
3. Investigations:
It
includes Routine hemogram, Serum biochemistry, Chest radiograph, High
resolution Tomography of thorax, Bronchoscopy with Bronchoalveolar lavage and
Transbronchial lung biopsy, Spirometry with DLCo (Diffusion capacity of lung
Carbon monoxide).
Statistical tools: The statistical analysis was done
using SPSS (statistical Package for social sciences) Version 15.0 statistical
Analysis Software. The values were represented in Number (%) and Mean ± SD.
The
following Statistical formulas were used:
1. Mean
2. Standard Deviation
3.
Analysis of Variance:
Results
Table-1: Showing different types of
DPLDs seen in this study
S.N. |
Type |
No. of Patients |
Percentage |
1 |
Idiopathic Pulmonary Fibrosis |
30 |
40.00 |
2 |
Sarcoidosis |
16 |
21.3 |
3 |
Non-Specific interstitial Pneumonia |
5 |
6.7 |
4 |
Rheumatoid Arthritis |
5 |
6.7 |
5 |
Systemic Lupus Erythematosus |
3 |
4 |
6 |
Systemic Sclerosis |
3 |
4 |
7 |
Cryptogenic Organizing Pneumonia |
2 |
2.7 |
8 |
Eosinophilic Pneumonia |
2 |
2.7 |
9 |
Hypersensitivity Pneumonitis |
2 |
2.7 |
10 |
Lymphangioleomyomatosis |
2 |
2.7 |
11 |
Silicosis |
1 |
2.7 |
12 |
Drug Induced
Bronchiolitis Obliterans Organizing Pneumonia |
1 |
1.3 |
13 |
Drug Induced
Non-Specific Interstitial Pneumonia |
1 |
1.3 |
14 |
Langerhans cell
histiocytosis |
1 |
1.3 |
Maximum number of cases
were found of Idiopathic pulmonary fibrosis and followed by sarcoidosis and
minimum cases of silicosis, Drug induced BOOP, Drug induced NSIP and Langerhans
cell histiocytosis.
Table-2: Distribution of patients according to Grouped Diagnosis
S.N. |
Grouped Diagnosis |
No. of Patients |
Percentage |
1 |
Group I
(Granulomatous) (All cases of sarcoidosis |
16 |
21.2 |
2 |
Group I (IIP) (COP,
IPF, NSIP) |
37 |
49.3 |
3 |
Group III (Known)
(Drug induced BOOP, Drug induced NSIP, Silicosis, SLE |
15 |
20.00 |
4 |
Group IV (Others) (EP,
HP, LAM, LCH) |
7 |
9.3 |
Table
showing maximum number of patients fall under Group II having Idiopathic
interstitial pneumonias, second most common group is Group I containing
granulomatous type of diseases like sarcoidosis, Group III is having only 20%
of patients, Group IV is least common among all DPLDs.
Table 3: Distribution of patients according
to Demography includes age, sex, occupation etc.
S.N. |
Characteristics |
Group I (n=37) |
Group II (n=15) |
Group III (n=15) |
Group IV (n=7) |
Significance of difference |
||||||
|
|
No. |
% |
No. |
% |
No. |
% |
No. |
% |
ᵪ2 |
P |
|
1 |
Mean Age ⁺- SD (Range) |
37.06 ⁺-10.45 (25.65) |
55.57 ⁺-8.07 (35-70) |
|
49.33 ⁺-7.53 (35-60) |
|
40.17 ⁺-12.05 (30-60) |
F=18.272;
P<0.001 |
||||
2 |
Gender |
|
|
|
|
|
|
|
|
|
|
|
Male |
7 |
43.8 |
22 |
59.5 |
5 |
33.3 |
3 |
42.9 |
3.371 |
0.338 |
||
Female |
9 |
56.3 |
15 |
40.5 |
10 |
66.7 |
4 |
57.1 |
||||
3 |
Smoke |
1 |
6.3 |
13 |
35.1 |
2 |
13.3 |
2 |
28.6 |
6.295 |
0.098 |
|
4 |
Education |
|
|
|
|
|
|
|
|
|
|
|
Illiterate |
2 |
12.5 |
18 |
48.6 |
6 |
40.00 |
1 |
14.3 |
12.488 |
0.187 |
||
Primary |
0 |
0.00 |
2 |
5.4 |
0 |
0.00 |
0 |
0.00 |
||||
HS/Inter |
6 |
37.5 |
9 |
24.3 |
6 |
40.00 |
3 |
42.9 |
||||
Graduate & Above |
8 |
50.00 |
8 |
21.6 |
3 |
20.00 |
3 |
42.9 |
||||
5 |
Occupation |
|
|
|
|
|
|
|
|
|
|
|
Housewife |
8 |
50.00 |
12 |
32.4 |
7 |
46.7 |
3 |
42.9 |
8.097 |
|
||
Agriculture/ Labour |
0 |
0.00 |
13 |
35.1 |
4 |
26.7 |
2 |
28.6 |
||||
Service |
8* |
50.00 |
12 |
32.4 |
4 |
26.7 |
2 |
28.6 |
||||
Table-4: Distribution of patients according to Clinical
Findings
S.N. |
Characteristics |
Group I (n=16) |
Group II (n=37) |
Group III (n=15) |
Group IV (n=7) |
Significance of difference |
|||||
|
|
No. |
% |
No. |
% |
No. |
% |
No. |
% |
ᵪ2 |
P |
1 |
Chest
Pain |
9 |
56.2 |
3 |
8.1 |
3 |
20 |
1 |
14.3 |
15.703 |
0.001 |
2 |
Fever |
11 |
81.30 |
2 |
5.4 |
4 |
26.7 |
2 |
28.6 |
23.765 |
<0.001 |
3 |
Dry
cough |
4 |
25 |
15 |
40.5 |
4 |
26.7 |
1 |
14.3 |
2.806 |
0.422 |
4 |
Breathlessness |
5 |
31.2 |
37 |
100 |
12 |
80 |
7 |
100 |
36.55 |
<0.001 |
5 |
Pedal
edema |
1 |
6.3 |
7 |
18.9 |
0 |
0 |
0 |
0 |
5.599 |
0.133 |
6 |
Cyanosis |
1 |
6.3 |
14 |
37.8 |
0 |
0 |
0 |
0 |
14.749 |
0.002 |
7 |
Lymphadenopathy |
5 |
31.3 |
0 |
0 |
0 |
0.00 |
0 |
0 |
19.754 |
<0.001 |
8 |
Clubbing |
0 |
0.00 |
19 |
52.3 |
2 |
13.30 |
0 |
0.00 |
20.553 |
<0.001 |
9 |
JVP
R |
0 |
0 |
8 |
21.6 |
1 |
6.70 |
0 |
0 |
6.784 |
0.079 |
10 |
Other
|
2 |
12.50 |
0 |
0 |
12 |
80.00 |
1 |
14.3 |
43.705 |
<0.001 |
This
tableShowing clinical symptoms in different of DPLDs. Breathless is most common complaint, Constitutional symptom like
fever and chest pain are more common in DPLDs associated with connective tissue
disorders.
Discussion
DPLD is a
group of diseases which include IPF, Sarcoidosis and many other forms. In this
study total 75 patients were assessed clinically as well as radiologically with
Spirometry and DLCO. Best approach to patients with DPLD begins with careful
history and examinations followed by Chest radiographs and Pulmonary function
test [5].
After
careful history and examinations along with investigations we found total 14
types of DPLD (Table-1). For the
study we divided the DPLDs in four Groups (Table-2).
Group I (Granulomatous) all sarcoidosis contains 16 patients (21.3%). Group II
(IIP) COP, IPF, NSIP contains 37 patients (49.3%). Group III (Known, BOOP, Drug
induced, Silicosis, SLE etc) contains 15 patients, Group IV (others EP, HP,
LAM, LCH) contains 7 patients (9.3%). In our study Group II containing maximum
number of patients 49.3%. next most common group diagnosed was Group I
(granulomatous, all cases were sarcoidosis. Total 30(40.0 %) patients were
diagnosed as IPF. Sarcoidosis 16(1.3%), NSIP 5(6.7%) etc. The yearly prevalence
of IPF was 20.2 per 100,000 population in males and 13.2 per 100,000
populations in females. [13]. the study referenced [13] shows maximum no. of
patients with IPF followed by Sarcoidosis is comparable to our study.
Demographic
distribution is done in Table 3. Showing
age of patients ranged from 25 to 70 years. Mean age of subjects in group I was
minimum (37.06+/- 10.45 years) while that of Group II was maximum (55.57+/-
8.07 years). On comparing data a significant Difference among groups was
observed (p<0.001). There is no significant intergroup difference was
observed between male and female (p<0.338). The proportion of Smokers ranged
12.5% in group I to 48.6% in group II, however despite this inter group
variability, Statistical difference was not significant.
In Table-4 Distribution of patients
according to clinical findings was observed. In group I Fever (81.3%) and chest
pain (56.2%) were most common clinical findings as compared to other groups.
These were significantly higher in group I.The incidence of patients with
breathlessness in this group was lower as compared to other groups. Whereas all
the patients had breathlessness. In Group II breathlessness was the most common
finding (100%). Other common findings were Clubbing (52.3%) and cyanosis
(37.8%).In Group III all the patients had Breathlessness. Group III had many
associated problems. Categorized together as others. The incidence of other
findings (80%) was significantly higher in group III as compared to other groups.
In Group IV all the subjects had breathlessness.
The
clinical history includes the symptoms like breathlessness, cough etc&
their progression and clinical course. Comorbid diseases like collagen vascular
disease should be sought in mind in case of DPLDs associated with SLE (Systemic
Lupus Erythematosus) & RA (Rheumatoid Arthritis). A record of environmental
factors like smoking status, drug use and occupational history is important to
diagnose ILD associated with occupational Lung Diseases.
Physical
examination is very important and sings like finger clubbing, cyanosis, reynods
phenomenon must be evaluated. in case of joint pain and tight skin collagen
vascular diseases must be assessed. After detailed history and examination
investigation must include chest radiograph, High resolution CT. Further
bronchoscopy with Bronchoalveolar lavage, Transbronchial lung biopsy,
Endobronchial biopsy should be done. For assessment of lung function Pulmonary
function test and DLco are important investigating tools.
HRCT (High
resolution CT) should be done with established Guidelines [6 & 7]. In more
than 50% cases suspected of IPF (idiopathic pulmonary fibrosis) the presence of
typical clinical and HRCT features of UIP (usual interstitial pneumonia) that
is honey combing and lower subpleural predominance is sufficient to allow a
confidant diagnosis of IPF and it eliminates need of surgical lung biopsy [8
& 5]. HRCT (High resolution CT) also provide important clues for NON-IIP
diseases like Sarcoidosis [9]. DPLD affects not only interstitial space but also
the air spaces, Peripheral airways, and vessels along with epithelial and
endothelial linings [10]. Patients are commonly misclassified as IIP because of
Inadequate history and examinations. There are increased association between
the development of DPLD and Occupational, environmental and drug exposure
[11,12].
Connective
tissue disorder related DPLDs belong to Lower age group patients [14]. In this
study mean age for diseases associated with Connective tissue disorder is 49.33
years. Pulmonary Symptom and
sign among CTD-ILD were similar to IPF, except clubbing, which is uncommon in
CTD related ILDs [15]. The annual prevalence of Idiopathic pulmonary
fibrosis was 20.2 per 100000 population in males and 13.2 per 100000 in females
[2]. IPF is also found in maximum number in this study.
Number of
clinicopathological types, they are sufficiently different from one another
designated as separate disease. they can be clearly distinguished from others
by detailed clinical history and examinations, chest radiology and other
laboratory findings.
India is a
high burden country for tuberculosis. Many patients with Interstitial disease
are mis diagnosed to be with Tuberculosis and receive antitubercular drugs.
[14]. So clinical history and investigations including sputum microscopy for
acid fast bacilli is very important to rule out Tuberculosis.
Conclusion
Diffuse parenchymal
lung disease is a group of multiple disorders. Clinical presentation of
different types is almost similar which includes symptoms like breathlessness,
dry cough, along with systemic symptoms like fever, chest pain etc, joint pain
and other constitutional symptoms are more common in connective tissue
disorders related DPLDs. Clinical history and radiology is very important for
correct diagnosis of DPLDs. [5]. Idiopathic interstitial pneumonia is more
common. Idiopathic pulmonary fibrosis is most common entity followed by
granulomatous disease like sarcoidosis. High resolution computed tomography
(HRCT) thorax is very important and in case of good clinical history and
examination a good quality HRCT thorax can leads near precise diagnosis and
eliminate need of Biopsy [8&9].
What the study adds to existing
knowledge: DPLDs
are not properly diagnosed till date due to lack of proper data. There is no
cure for many types of DPLDs. This study confirms the data which were already
present and strengthens the need of good clinical evaluation and radiological
findings. As biopsy is not possible in each and every case due to many reasons,
clinical and radiological evaluation is important in diagnosis of different
type of DPLDs.
Authors Contribution: (1) Dr. Harendra Yadav: Selection of
patients,their clinical evaluation and investigations was done by Dr Harendra
Yadav. Helped in manuscript writing. (2) Dr Rahul Srivastava: Collection and
compilation of data, evaluation and interpretation of master chart, review of
literature and references were obtained by Dr Rahul Srivastava. Manuscript
writing is done by Dr Rahul Srivastava.
References
1. Raghu
G. Interstitial lung disease. In: Goldman L, Schafer AI, editors Cecil
Medicine; 24th editon. Philadelphia: W.B. Saunders;2011:pp556-66.
2. Coultas
DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung
diseases. DOI:10.1164/ajrccm.150.4.7921471.[pubmed]
3.
Morgenthau AS, Padilla ML. Spectrum of fibrosing diffuse parenchymal lung
disease. DOI:10.1002/msj.20087.[pubmed]
4. Jindal
SK, Malik SK, Deodhar SD, Sharma BK. Fibrosing alveolitis: a report of 61 cases
seen over the past five years. Indian J Chest Dis Allied Sci. 1979
Oct-Dec;21(4):174-9.[pubmed]
5. Raghu G, Mageto YN, Lockhart D, et al. The accuracy of the clinical
diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial
lung disease: A prospective study. Chest. 1999 Nov;116(5):1168-74.[pubmed]
6. American College of Radiology. Practice
guideline for the breast conservation therapy in the management of invasive
breast carcinoma. DOI:10.1016/j.jamcollsurg.2007.02.057
7. Austin
JH, Müller NL, Friedman PJ, et al. Glossary of terms for CT of the lungs:
recommendations of the Nomenclature Committee of the Fleischner Society.
DOI:10.1148/radiology.200.2.8685321.[pubmed]
8.
Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for
the diagnosis of idiopathic pulmonary fibrosis.
DOI:10.1164/ajrccm.164.2.2101090.[pubmed]
9. Honda
O, Johkoh T, Ichikado K, et al. Comparison of high resolution CT findings of
sarcoidosis, lymphoma, and lymphangitic carcinoma: is there any difference of
involved interstitium? J Comput Assist Tomogr. 1999 May-Jun;23(3):374-9.[pubmed]
10.
Cushley MJ, Davison AG, du Bois RM, Egan J, Flower CD, Gibson GJ, Greening AP,
Ibrahim NB, Johnston ID, Mitchell DM, et al. The diagnosis, assessment and
treatment of diffuse parenchymal lung disease in adults. Thorax 1999;54:S1–S30.
11.
Hubbard R, Venn A, Smith C, et al. Exposure to commonly prescribed drugs and
the etiology of cryptogenic fibrosing alveolitis: a case-control study.
DOI:10.1164/ajrccm.157.3.9701093
12. Scott
J, Johnston I, Britton J. What causes cryptogenic fibrosing alveolitis? A
case-control study of environmental exposure to dust. BMJ. 1990 Nov
3;301(6759):1015-7. [pubmed]
13. Kundu
S, Mitra S, Ganguly J, et al. Spectrum of diffuse parenchymal lung diseases
with special reference to idiopathic pulmonary fibrosis and connective tissue
disease: An eastern India experience. DOI:10.4103/0970-2113.142115
14.
Udwadia ZF, Sen T, Jindal SK. Interstitial lung diseases in a resource-limited
setting: The case of India. Eur
Respir Mon 2009;46:357-74.
15. Rajasekaran BA, Shovlin D, Lord P, et al. Interstitial
lung disease in patients with rheumatoid arthritis: a comparison with
cryptogenic fibrosing alveolitis. Rheumatology (Oxford). 2001 Sep;40(9):1022-5.[pubmed]